financetom
Business
financetom
/
Business
/
Adhesives maker H.B. Fuller Q3 adjusted profit edges above expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Adhesives maker H.B. Fuller Q3 adjusted profit edges above expectations
Sep 24, 2025 1:23 PM

Overview

* H.B. Fuller ( FUL ) fiscal Q3 revenue declines 2.8%, slightly below analyst expectations, per LSEG data

* Adjusted EPS for fiscal Q3 rises 12% and edges past analyst estimates

* Adjusted EBITDA increases 3% yr/yr, surpassing analyst expectations

Outlook

* Company expects fiscal 2025 net revenue to decline 2% to 3%

* H.B. Fuller ( FUL ) sees fiscal 2025 adjusted EBITDA at $615 mln to $625 mln

* Company anticipates fiscal 2025 adjusted EPS of $4.10 to $4.25

* H.B. Fuller ( FUL ) expects fiscal 2025 cash flow from operations of $275 mln to $300 mln

Result Drivers

* PRICING AND COST ACTIONS - Adjusted gross profit margin increased by 190 basis points year-on-year, driven by favorable net pricing and raw material cost actions

* DIVESTITURE IMPACT - Adjusted for the flooring divestiture, net revenue was up 1.6% year-on-year

* COST REDUCTION - Targeted cost reduction efforts contributed to the increase in adjusted gross profit margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $892 mln $895.80

Revenue mln (6

Analysts

)

Q3 Beat $1.26 $1.24 (6

Adjusted Analysts

EPS )

Q3 Beat $69 mln $68.60

Adjusted mln (5

Net Analysts

Income )

Q3 Beat $171 mln $169.20

Adjusted mln (6

EBITDA Analysts

)

Q3 $288 mln

Adjusted

Gross

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the specialty chemicals peer group is "buy."

* Wall Street's median 12-month price target for H.B. Fuller Company ( FUL ) is $72.00, about 17.2% above its September 23 closing price of $59.62

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Adobe reworks its apps for AI assistants, pursues ChatGPT integration
Adobe reworks its apps for AI assistants, pursues ChatGPT integration
Oct 28, 2025
SAN FRANCISCO, Oct 28 (Reuters) - Adobe said on Tuesday its video and image editing tools can be controlled by chatting with them, adding that it is working with ChatGPT creator OpenAI to let users directly control one of its apps with the popular chatbot service. Adobe is the creator of Photoshop and Premiere, widely used tools in the photography...
US M&A momentum accelerates: EY-Parthenon forecasts 2026 deal activity to surpass 2025
US M&A momentum accelerates: EY-Parthenon forecasts 2026 deal activity to surpass 2025
Oct 28, 2025
Dealmakers shift from recovery to resilient growth, driven by strategic AI-driven transformation. Resilient volume growth: Total US deal volume (for deals more than $100 million) is expected to grow 3% in 2026, following an anticipated 9% rise in 2025. Surge in deal value will continue: Year-to-date deal value is up 36% over 2024, driven by a strong uptick in larger deals that...
ORACLE says there is real value in AI as demand far outpaces supply
ORACLE says there is real value in AI as demand far outpaces supply
Oct 28, 2025
RIYADH, Oct 28 (Reuters) - Oracle CEO Mike Sicilia said on Tuesday that he is not concerned about an AI bubble, adding that there is real value in artificial intelligence as demand far outpaces supply. He was speaking at a panel the annual Future Investment Initiative (FII) summit in Riyadh. ...
Incyte boosts annual sales forecast of blood cancer drug after strong quarter
Incyte boosts annual sales forecast of blood cancer drug after strong quarter
Oct 28, 2025
Oct 28 (Reuters) - Drugmaker Incyte Corp on Tuesday raised its annual sales forecast for its blood cancer treatment Jakafi after robust demand for the drug helped the company surpass Wall Street estimates for third-quarter revenue and profit. However, shares fell 2.4% in premarket trading after the company said it halted two new drug programs and stopped developing povorcitinib for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved